PCSA advances VT-7208 into phase II trials
PCSA said a recent merger and a $200 million PIPE position it to advance VT-7208, a next-generation BTK inhibitor, into three parallel phase II trials targeting food allergy, CSU and relapsing MS.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.